These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2194 related articles for article (PubMed ID: 31319971)
1. Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis. Dafni U; Tsourti Z; Vervita K; Peters S Lung Cancer; 2019 Aug; 134():127-140. PubMed ID: 31319971 [TBL] [Abstract][Full Text] [Related]
2. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer. Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104 [TBL] [Abstract][Full Text] [Related]
3. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer. Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176 [TBL] [Abstract][Full Text] [Related]
4. Rational application of the first-line chemotherapy and immune checkpoint inhibitors in advanced nonsmall cell lung cancer: A meta-analysis. Cao R; Ma JT; Zhang SL; Sun L; Liu Y; Zhang XY; Jing W; Huang LT; Han CB Cancer Med; 2019 Sep; 8(11):5033-5046. PubMed ID: 31297962 [TBL] [Abstract][Full Text] [Related]
5. First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy. Zhou Y; Lin Z; Zhang X; Chen C; Zhao H; Hong S; Zhang L J Immunother Cancer; 2019 May; 7(1):120. PubMed ID: 31053172 [TBL] [Abstract][Full Text] [Related]
6. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis. Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993 [TBL] [Abstract][Full Text] [Related]
7. Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1? Zhang Y; Zhou H; Zhang L J Immunother Cancer; 2018 Dec; 6(1):135. PubMed ID: 30509312 [TBL] [Abstract][Full Text] [Related]
8. Comparative long-term outcomes of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy as first-line therapy for metastatic non-small-cell lung cancer: a systematic review and network meta-analysis. Huang S; Huang Z; Huang X; Luo R; Liang W; Qin T Front Immunol; 2024; 15():1375136. PubMed ID: 39072325 [TBL] [Abstract][Full Text] [Related]
9. Identifying optimal first-line interventions for advanced non-small cell lung carcinoma according to PD-L1 expression: a systematic review and network meta-analysis. Liu J; Li C; Seery S; Yu J; Meng X Oncoimmunology; 2020; 9(1):1746112. PubMed ID: 32313723 [TBL] [Abstract][Full Text] [Related]
10. Immunotherapy Alone or in Combination with Chemotherapy as First-Line Treatment of Non-Small Cell Lung Cancer. Saxena P; Singh PK; Malik PS; Singh N Curr Treat Options Oncol; 2020 Jul; 21(8):69. PubMed ID: 32720019 [TBL] [Abstract][Full Text] [Related]
11. A systematic review and network meta-analysis of first-line immune checkpoint inhibitor combination therapies in patients with advanced non-squamous non-small cell lung cancer. Shao T; Zhao M; Liang L; Tang W Front Immunol; 2022; 13():948597. PubMed ID: 36389713 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of anti-PD-1/PD-L1 in combination with chemotherapy or not as first-line treatment for advanced non-small cell lung cancer: A systematic review and network meta-analysis. Wang L; Yang Y; Yu J; Zhang S; Li X; Wu X; Nie X; Liu W; Zhang P; Li Y; Li A; Ai B Thorac Cancer; 2022 Feb; 13(3):322-337. PubMed ID: 34907661 [TBL] [Abstract][Full Text] [Related]
13. Comparison of efficacy and safety of PD-1/PD-L1 combination therapy in first-line treatment of advanced NSCLC: an updated systematic review and network meta-analysis. Yang Y; Chen W; Dong L; Duan L; Gao P Clin Transl Oncol; 2024 Oct; 26(10):2488-2502. PubMed ID: 38625495 [TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies. Nosaki K; Saka H; Hosomi Y; Baas P; de Castro G; Reck M; Wu YL; Brahmer JR; Felip E; Sawada T; Noguchi K; Han SR; Piperdi B; Kush DA; Lopes G Lung Cancer; 2019 Sep; 135():188-195. PubMed ID: 31446994 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of first-line checkpoint inhibitors-based treatments for non-oncogene-addicted non-small-cell lung cancer: a systematic review and meta-analysis. Siciliano MA; Caridà G; Ciliberto D; d'Apolito M; Pelaia C; Caracciolo D; Riillo C; Correale P; Galvano A; Russo A; Barbieri V; Tassone P; Tagliaferri P ESMO Open; 2022 Jun; 7(3):100465. PubMed ID: 35427835 [TBL] [Abstract][Full Text] [Related]
16. The impact of high PD-L1 expression on the surrogate endpoints and clinical outcomes of anti-PD-1/PD-L1 antibodies in non-small cell lung cancer. Ito K; Miura S; Sakaguchi T; Murotani K; Horita N; Akamatsu H; Uemura K; Morita S; Yamamoto N Lung Cancer; 2019 Feb; 128():113-119. PubMed ID: 30642442 [TBL] [Abstract][Full Text] [Related]
17. The landscape of immune checkpoint inhibitor plus chemotherapy versus immunotherapy for advanced non-small-cell lung cancer: A systematic review and meta-analysis. Wang C; Qiao W; Jiang Y; Zhu M; Shao J; Wang T; Liu D; Li W J Cell Physiol; 2020 May; 235(5):4913-4927. PubMed ID: 31693178 [TBL] [Abstract][Full Text] [Related]
18. Comparison of Efficacy and Safety of Single and Double Immune Checkpoint Inhibitor-Based First-Line Treatments for Advanced Driver-Gene Wild-Type Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis. Xu Q; Zhang X; Huang M; Dai X; Gao J; Li S; Sheng L; Huang K; Wang J; Liu L Front Immunol; 2021; 12():731546. PubMed ID: 34484242 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of immune checkpoint inhibitors for advanced non-small cell lung cancer with or without PD-L1 selection: A systematic review and network meta-analysis. Li Y; Liang X; Li H; Chen X Chin Med J (Engl); 2023 Sep; 136(18):2156-2165. PubMed ID: 37596898 [TBL] [Abstract][Full Text] [Related]
20. Comparative efficacy and safety of PD-1/PD-L1 immunotherapies for non-small cell lung cancer: a network meta-analysis. Wang DD; Shaver LG; Shi FY; Wei JJ; Qin TZ; Wang SZ; Kong YJ Eur Rev Med Pharmacol Sci; 2021 Apr; 25(7):2866-2884. PubMed ID: 33877652 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]